AAAAAA

   
Results: 1-10 |
Results: 10
Drug-drug interaction studies with mirtazapine and carbamazepine in healthy male subjects
Authors: Sitsen, JMA Maris, FA Timmer, CJ
Citation: Jma. Sitsen et al., Drug-drug interaction studies with mirtazapine and carbamazepine in healthy male subjects, EUR J DRUG, 26(1-2), 2001, pp. 109-121
Pharmacokinetics of etonogestrel and ethinylestradiol released from a combined contraceptive vaginal ring
Authors: Timmer, CJ Mulders, TMT
Citation: Cj. Timmer et Tmt. Mulders, Pharmacokinetics of etonogestrel and ethinylestradiol released from a combined contraceptive vaginal ring, CLIN PHARMA, 39(3), 2000, pp. 233-242
Clinical pharmacokinetics of mirtazapine
Authors: Timmer, CJ Sitsen, JMA Delbressine, LP
Citation: Cj. Timmer et al., Clinical pharmacokinetics of mirtazapine, CLIN PHARMA, 38(6), 2000, pp. 461-474
Pharmacokinetics of mirtazapine and lithium in healthy male subjects
Authors: Sitsen, JMA Voortman, G Timmer, CJ
Citation: Jma. Sitsen et al., Pharmacokinetics of mirtazapine and lithium in healthy male subjects, J PSYCHOPH, 14(2), 2000, pp. 172-176
Concomitant use of mirtazapine and cimetidine: a drug-drug interaction study in healthy male subjects
Authors: Sitsen, JMA Maris, FA Timmer, CJ
Citation: Jma. Sitsen et al., Concomitant use of mirtazapine and cimetidine: a drug-drug interaction study in healthy male subjects, EUR J CL PH, 56(5), 2000, pp. 389-394
Bioavailability and bioequivalence of etonogestrel from two oral formulations of desogestrel: Cerazette (R) and Liseta (R)
Authors: Timmer, CJ Srivastava, N Dieben, TOM Cohen, AF
Citation: Cj. Timmer et al., Bioavailability and bioequivalence of etonogestrel from two oral formulations of desogestrel: Cerazette (R) and Liseta (R), EUR J DRUG, 24(4), 1999, pp. 335-343
Bioequivalence assessment of three different estradiol formulations in postmenopausal women in an open, randomized, single-dose, 3-way cross-over study
Authors: Timmer, CJ Geurts, TBP
Citation: Cj. Timmer et Tbp. Geurts, Bioequivalence assessment of three different estradiol formulations in postmenopausal women in an open, randomized, single-dose, 3-way cross-over study, EUR J DRUG, 24(1), 1999, pp. 47-53
Pharmacokinetic and pharmacodynamic characteristics of ganirelix (Antagon/Orgalutran). Part I. Absolute bioavailability of 0.25 mg of ganirelix after a single subcutaneous injection in healthy female volunteers
Authors: Oberye, JJL Mannaerts, BMJL Kleijn, HJ Timmer, CJ
Citation: Jjl. Oberye et al., Pharmacokinetic and pharmacodynamic characteristics of ganirelix (Antagon/Orgalutran). Part I. Absolute bioavailability of 0.25 mg of ganirelix after a single subcutaneous injection in healthy female volunteers, FERT STERIL, 72(6), 1999, pp. 1001-1005
Pharmacokinetic and pharmacodynamic characteristics of ganirelix (Antagon/Orgalutran). Part II. Dose-proportionality and gonadotropin suppression after multiple doses of ganirelix in healthy female volunteers
Authors: Oberye, JJL Mannaerts, BMJL Huisman, JAM Timmer, CJ
Citation: Jjl. Oberye et al., Pharmacokinetic and pharmacodynamic characteristics of ganirelix (Antagon/Orgalutran). Part II. Dose-proportionality and gonadotropin suppression after multiple doses of ganirelix in healthy female volunteers, FERT STERIL, 72(6), 1999, pp. 1006-1012
Enterohepatic cycling and pharmacokinetics of oestradiol in postmenopausalwomen
Authors: Vree, TB Timmer, CJ
Citation: Tb. Vree et Cj. Timmer, Enterohepatic cycling and pharmacokinetics of oestradiol in postmenopausalwomen, J PHARM PHA, 50(8), 1998, pp. 857-864
Risultati: 1-10 |